Covid-19 News and Discussions

@Sharma Ji

Thank goodness I didn't take that AZ junk.


AstraZeneca’s Covid vaccine is no more – but its remarkable success must not be forgotten​

Robin McKieScience editor
Although dogged by controversy, the firm’s coronavirus jab saved the lives of millions and helped avert humanitarian crises in nations unable to access costly alternatives

Sat 11 May 2024 15.29 BST
Share


Last week’s announcement that AstraZeneca would no longer market its Covid vaccine brings an end to one of the century’s most remarkable medical stories. Created within a year of the arrival of the pandemic, the AZ vaccine was cheap, easily stored and transported, and helped stave off humanitarian crises in Asia and Latin America, where many countries could not afford the more expensive mRNA vaccines that were being snapped up by rich western nations. It is estimated that it saved 6.3 million lives in 2021 alone.
Yet from the start the vaccine – created by research teams led by Professor Andy Pollard and Professor Sarah Gilbert at the Oxford Vaccine Centre – was dogged by controversy. It was linked to blood clots, US observers criticised protocols for its trials, and French president Emmanuel Macron claimed it was “quasi-ineffective” for people over 65. In fact, the vaccine is particularly effective for the elderly.


In very rare cases, the AZ vaccine can cause blood clots. According to the British Heart Foundation, one study in the BMJ showed that for every 10 million people vaccinated with AstraZeneca there would be a total of 73 extra cases of blood clots. By contrast 10 million Covid cases would trigger thousands of extra blood clot cases.
Many of the anxieties about the vaccine stemmed from national self-interests. However, others derive from the nature of vaccines themselves, and this raises issues that are likely to re-emerge with the arrival of any new pandemic in coming years, scientists have warned.
A vaccine is unlike any other type of medicine because it works by stimulating a person’s anti-pathogen defences, arming them in advance of a future infection. However, this preparation goes beyond helping one individual and can aid the general population, a point stressed by Professor Stephen Evans, of the London School of Medicine and Tropical Hygiene.
“If I take a preventative drug – such as a statin – then I am the only one who benefits,” said Evans. “However, there are people who cannot mount responses to a vaccine because they are ill or have a weakened immune system. They remain vulnerable. However, if you can build up herd immunity by ensuring the maximum number of people are inoculated, virus levels will drop and the vulnerable will be protected. If we believe we have responsibilities to help others, being vaccinated achieves that. There are moral concerns about being inoculated, in other words.”

Convincing the public – which has witnessed a rise in anti-vax propaganda in recent years – of this may not be easy. In addition, there is a second crucial difference between standard medical treatments and vaccines, added Professor Sir David Spiegelhalter, of the University of Cambridge. “We never know the identities of those who benefit [from a vaccine] – they are ‘statistical’ people – while those who are harmed can be named and their stories told.”
AstraZeneca’s Covid vaccine provides an example. We only know those who were harmed by it but cannot pinpoint those who benefited. Again, this makes it trickier to pinpoint a vaccine’s success and assure people of its efficacy. “To a certain extent, you can get round this and assess the impact of Covid vaccines by looking at the deaths of frontline workers in the health service during the pandemic’s early days,” added Evans. “Hundreds died, but if we had had a vaccine then it is now clear most would probably have survived.”
Most virologists and vaccine experts agree: when you look at the AstraZeneca vaccine from a global perspective, it probably benefited tens of millions of people, preventing deaths and reducing long-term consequences of Covid. It was a remarkable success, yet its passing has been marked by many who stressed its side-effects but never touched on its achievements.
“The paradox of vaccines is that people forget how important they are,” said Professor Adam Finn, of Bristol University. “They are like democracy. You enjoy it for a while and then forget how important it is to preserve it. It’s a problem.”
skip past newsletter promotion
Sign up to Observed

Free weekly newsletter
Analysis and opinion on the week's news and culture brought to you by the best Observer writers
Enter your email address
Sign up


Privacy Notice: Newsletters may contain info about charities, online ads, and content funded by outside parties. For more information see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.
after newsletter promotion
AstraZeneca vaccines
AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines
Read more
On the other hand, it is also clear politicians and officials will have to be careful about the claims they make, added Fiona Fox, head of the Science Media Centre. “Public trust in vaccines will come from open and honest communication. The benefits massively outweigh the risks as they did with this vaccine.
“But you won’t win any arguments by claiming that vaccines are 100% safe or running for the hills at the first reports of problems, which unfortunately too many government and NHS communications officers tend to do.
Downplaying risks is always tempting when you need people to take a mostly safe vaccine but it’s ultimately self-defeating because it erodes trust in the longer term.”
Pfizer and Moderna just as bad.

The Indian ones, non mRNA a bit safer, but I never took.

Beefy gym guy in my neighborhood died, left behind a young wife and kid
. He wasn't even sick.

Covid is a hoax and all the vaccines mean death.
 
Remember that trendy thing where people were uploading vids and pics of taking the jab ? 😆 🤣 😂
 

Will your last COVID vaccine work against new ‘FLiRT’ variants?​

BY ADDY BINK - 05/12/24 10:18 AM ET
SHAREPOST


Video Player is loading.
What is a COVID-19 variant?

Advertisement: 0:01






bob_003.gif

(NEXSTAR) — There are two new COVID-19 variants circulating, posing a threat to a summer surge.
The Centers for Disease Control and Prevention has been tracking the new variants, scientifically known as KP.2 and KP.1.1 since at least the start of 2024. They’ve been steadily growing in prominence ever since, and have garnered the nickname “FLiRT” because of their mutations.

The latest data shows KP.2 is the dominant strain in the U.S., comprising almost 25% of the tests that have been sequenced. KP.1.1 makes up about 8% as of the end of April. Both are sublineages of the JN.1 lineage of the Omicron variant, the main COVID variant for roughly three years.
Both FLiRT variants are considered very similar to JN.1, health officials say, with early data suggesting only a couple of changes in their spike proteins.
RFK Jr. had a brain worm. How do you get one and what are the symptoms?
With the virus expected to spread as the summer months approach, it may be sparking concerns about whether the last vaccine dose you received is still protecting you. Ultimately, it depends on when you got your last dose.
In fall, an updated COVID vaccine was released. The CDC has recommended everyone 6 months old and older get the updated vaccines from Pfizer-BioNTech, Moderna, or Novavax. In February, a federal immunization committee voted in favor of recommending an additional dose for those ages 65 and up. Those between the ages of 6 months and 4 years old require multiple doses, the CDC says.
Previously, health officials have said the COVID vaccines would provide protection from the virus for “several months.” In a February update on the newest vaccine booster made available in September, the CDC said that while it had (from September to January) been effective, they expected that protection would “decline over time” as had been seen with previous doses.
However, because the FLiRT variants are relatively new, there isn’t enough data to show whether the vaccine or immunity from a recent case of COVID will provide effective protection against them.

Speaking with TODAY, Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, said lab studies so far have shown vaccines and immunity may only provide partial protection. Late last month, the World Health Organization recommended that future COVID vaccines formulations be based on the JN.1 variant, a close relative of the FLiRT off-shoots that reigned as the most common in the U.S. over the last few months.
As of Thursday, the CDC is reporting minimal COVID activity in wastewater nationwide, and virus-related hospitalizations and deaths, as well as the rate of patients visiting emergency departments testing positive for COVID, are down.
Here’s how much the average American has in their retirement savings by age
A spokesperson for the CDC tells Nexstar that the agency is “working to better understand [KP.2 and KP.1.1]’s potential impact on public health,” but notes that based on lab tests, there are “low levels of SARS-CoV-2 transmission overall at this time.”

“That means that while KP.2 is proportionally the most predominant variant, it is not causing an increase in infections as transmission of SARS-CoV-2 is low,” the spokesperson added. “Based on current data there are no indicators that KP.2 would cause more severe illness than other strains. CDC will continue to monitor community transmission of the virus and how vaccines perform against this strain.”
It’s too soon to say whether a new COVID vaccine will be created for the summer months. While the CDC recently eased guidance surrounding COVID, the agency still recommends everyone 6 months old and older get the updated COVID vaccine released in fall, if they haven’t already. Health experts are also continuing to encourage testing if you experience symptoms or are exposed, staying home if you’re sick, practicing good hygiene, and wearing a mask and social distancing when in public.
 

Time for a spring COVID-19 vaccine update for individuals 65 years+​

Individuals in this age group receive an additional dose of COVID-19 vaccine this spring to provide added protection as immunity may have decreased over time
BayToday Staffabout 2 hours ago





jeremy-bezanger-unsplash-covid-19-omicron-needles-vaccine
Jeremy Bezanger on Unsplash
Listen to this article
00:01:30

Dr. Kieran Moore, Ontario's Chief Medical Officer of Health Individuals says seniors aged 65 years and over are at increased risk of severe illness from COVID-19.

He is recommending that individuals in this age group receive an additional dose of COVID-19 vaccine this spring to provide added protection as immunity may have decreased over time.
Eligible people may receive a COVID-19 vaccine if it has been six months since their previous dose or confirmed COVID-19 infection unless a shorter interval is specifically recommended by a health care provider.
You can book a COVID-19 vaccine through:
 

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial​

Reuters |
May 13, 2024 12:58 PM IST

SHIONOGI-CORONAVIRUS-PILL: Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial​

TOKYO - Japan's Shionogi & Co said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically significant reduction of 15 common symptoms of the illness in a global, late-stage trial.
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial

The company's pivotal Phase 3 study of ensitrelvir did however demonstrate a potent antiviral effect compared to placebo, the company said.
Unlock exclusive access to the latest news on India's general elections, only on the HT App. Download Now! Download Now!

WHY IT'S IMPORTANT
Shionogi said previously it expected the pill, known commercially as Xocova, to deliver $2 billion in annual sales if it secured U.S. approval.
Xocova would compete with Pfizer's antiviral drug Paxlovid.
Shionogi's CEO told the Nikkei newspaper in March that the company expected to be able to sell the drug in the U.S. in early 2025.
CONTEXT
Xocova was granted emergency approval by Japanese regulators in November 2022, making it the nation's first domestically produced oral treatment for COVID. It received full approval in Japan in March 2024.
The Japanese government bought 2 million courses of the drug, most of which remain unused and are set to be destroyed, according to a Kyodo report this month.

The drug was granted Fast Track designation by the U.S. Food and Drug Administration in 2023.
The SCORPIO-HR trial is a part of the U.S. National Institutes of Health's public-private partnership for COVID treatments and vaccines.
WHAT'S NEXT
The company said it will continue working with regulatory bodies to explore routes to making ensitrelvir available, without giving further details.
 

Study shows clear benefit from COVID-19 vaccination for heart failure patients​

This article has been provided by European Society of Cardiology and subjected to News-Medical.Net's review protocols, complying with its guidelines. To guarantee the article's authority, our editing team has highlighted the following features: verified accuracy, undergone scholarly review, sourced from a reliable authority, and meticulously scrutinized for errors. Modifications may be made to the article's style and length.

" style="box-sizing: border-box; background-color: transparent; color: rgb(95, 95, 95); text-decoration: none; transition: all 0.15s ease-out 0s; cursor: pointer; border: 0px; overflow-wrap: break-word;">Reviewed


May 13 2024European Society of Cardiology
Heart failure patients who are vaccinated against COVID-19 have an 82% greater likelihood of living longer than those who are not vaccinated, according to research presented today at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC). Heart Failure is a life-threatening syndrome affecting more than 64 million people worldwide.
Patients with heart failure should be vaccinated against COVID-19 to protect their health. In this large study of patients with heart failure, COVID-19 vaccination was associated with a lower likelihood of contracting the infection, being admitted to hospital because of heart failure, or dying from any cause during a six-month period compared with remaining unvaccinated."
Dr. Kyeong-Hyeon Chun, study author of the National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea
Previous studies have shown the safety of COVID-19 vaccination in patients with cardiovascular diseases including heart failure, and that COVID-19 outcomes are worse in patients with heart failure compared to those without heart failure. However, there has been little research on how vaccines work specifically in patients with heart failure. This nationwide, retrospective study examined the prognosis of heart failure patients according to COVID-19 vaccination status.
This study used the Korean National Health Insurance Service database, which covers nearly all residents of the Republic of Korea, to obtain information on vaccinations and clinical outcomes. Participants who received two or more doses of COVID-19 vaccine were defined as "vaccinated", and those who were not vaccinated or had received just one dose were defined as "unvaccinated".

Related Stories​

The study included 651,127 patients aged 18 years or older with heart failure. The average age was 69.5 years and 50% were women. Of the total study population, 538,434 (83%) were defined as vaccinated and 112,693 (17%) as unvaccinated. To control for factors that could influence the relationship between vaccination status and outcomes, the researchers performed 1:1 matching of vaccinated and unvaccinated patients according to age, sex, other health conditions (e.g. high blood pressure, diabetes, high cholesterol, etc.), income, and region of residence. This resulted in 73,559 vaccinated patients and 73,559 unvaccinated patients for the comparative analyses.
The median follow-up was six months. Vaccination was associated with an 82% lower risk of all-cause mortality, 47% lower risk of hospitalisation for heart failure, and 13% reduced risk of COVID-19 infection compared with no vaccination. Regarding cardiovascular complications, vaccination was associated with significantly lower risks of stroke, heart attack, myocarditis/pericarditis, and venous thromboembolism compared to no vaccination.
Dr. Chun said: "This was the first analysis of COVID-19 vaccine effectiveness in a large population of heart failure patients, and the first to show a clear benefit from vaccination. The study provides strong evidence to support vaccination in patients with heart failure. However, this evidence may not be applicable to all patients with heart failure, and the risks of vaccination should be considered in patients with unstable conditions."
 

Covid cases continue to rise driven by new FLiRT variants​

EXCLUSIVE

Covid cases increase for the third week in a row, according to the latest data from the UK Health Security Agency (UKHSA)​

A detail of a hand holding a lateral flow test that shows a positive result. (Photo by Richard Baker / In Pictures via Getty Images)
People are often contagious one to two days before feeling ill and are most infectious in the first five days after symptoms start (Photo: Richard Baker/InPictures/Getty)
author avatar image
By Tom Bawden
Science & Environment Correspondent
May 12, 2024 12:28 pm(Updated May 13, 2024 7:57 am)

Covid cases are continuing to rise in the UK as the new highly-contagious FLiRT variants spread rapidly throughout Britain.
After nearly four months at around the lowest levels for three years, Covid cases have increased for the third week in a row, driven by new variants together with waning immunity built up from vaccines and prior infections among the public.
The latest data showed that “positivity rates” from the virus through the UK Health Security Agency UKHSA’s surveillance system increased to 8.6 per cent compared with 6.8 per cent in the previous week – a rise of 26 per cent in a week.


The figures relate to the proportion of people who take a Covid test, not the overall population, but scientists said they do give a good rough indication of infection rates more generally.
The new UKHSA figures also showed that Covid hospitalisations increased to 3.28 per 100,000 compared with 2.50 per 100,000 in the previous week – a 31 per cent increase.
The FLiRT variants, known individually as KP.2 and KP.3, saw their combined share of UK Covid cases reach 42 per cent on 1 May, the latest day for which data is available – with scientists predicting they have since surpassed 50 per cent to become the new dominant variants.
“Once again, Covid-19 cases and hospitalisations have risen this week, so now is the time to get your spring vaccine if you’re eligible and haven’t already,” said Dr Mary Ramsay, director of public health programmes at the UK Health Security Agency (UKHSA).



“If you have symptoms of Covid-19 or flu try to stay at home as it helps protect others, especially those who are more vulnerable to these viruses. If you are unable to stay at home when unwell, consider wearing a mask.”
The latest increases have fuelled concerns that the UK could be at the start of a new Covid wave – although this is not expected to be anything like as big as seen in the run-up to Christmas – when 2.5 million, or 4.6 per cent of the UK population had Covid – in part because we are heading into the summer.
At the same time, the new subvariants are not as different from their “parents” as some previous subvariants were from theirs.
They involve only two key mutations from the JN.1 variant – which was first detected in September and quickly became the dominant variant – that mean it can spread more easily.
Furthermore, the mutations have been around before, earlier in the pandemic, in some previous variants – but not since JN.1 became the dominant variant.

As such, the population may have some enduring immunity to those mutations but its hard to be sure, scientists say – as effect of any given mutation varies according to the variant it’s found in and is difficult to predict.
“These new figures are a reminder that Covid is not ‘over’ – it’s not a thing of the past and is still causing, and will continue to cause, significant illness and even hospitalisations,” Simon Williams, of Swansea University, told i.



“Thankfully the worst of Covid is behind us, and we are fortunately highly unlikely to see significant sharp waves of deaths and hospitalisations anywhere near to the first few years of the pandemic,” he said.
Professor Lawrence Young, a virologist at Warwick University, added: “The latest data indicates that infections are on the rise. Of particular concern is a small increase in Covid-related hospitalisations.”
“The spread of new virus variants and waning immunity are a concern particularly for the most vulnerable – the elderly and those with an impaired immune system. While currently available vaccines are not a perfect match for these new variants, the spring booster jab should provide some protection,” he said.
One FLiRT variant sees a mutation, known as F, being replaced by another, known as L. The other involves mutation R being supplanted by mutation T – giving the main letters for the term FLiRT.
 

Alberta UCP to host town hall to discuss COVID-19 vaccines in children​














michael-franklin-1-5642543.jpg

Michael Franklin
CTVNewsCalgary.ca Senior Digital Producer
Follow |Contact
Updated May 13, 2024 9:37 p.m. EDT
Published May 13, 2024 3:47 p.m. EDT
Share
  • Link
  • X
  • Reddit
  • LinkedIn
  • Email
The United Conservative Party says it has gathered a panel of medical experts for a town hall meeting next month that's expected to discuss the safety of COVID-19 vaccines in children.
The meeting, called 'An Injection of Truth', is scheduled to take place June 17 at Calgary's Southside Victory Church.

According to the UCP's website, the meeting is expected to address what it claims is a 350 per cent increase in number of children who've died in Alberta since 2021 and points a finger at COVID-19 vaccination(opens in a new tab).
No data sources, age ranges, date range or causes of death are provided.

RELATED STORIES​

"Was your child killed or injured by a COVID shot? Do you have a story to tell? You should be heard," a statement about the town hall reads.
The meeting, organized by Calgary-Lougheed MLA Eric Bouchard, is advertised to discuss "current scientific data and victim statements" about the "negative impact of COVID mRNA injections" in children.
The current participants of the meeting are described by the UCP as Calgary pediatrician Dr. Eric Payne, Edmonton ER doctor Dr. William Makis, Dr. David Speicher, Dr. Craig Shoemaker, Dr. Jessica Rose, Bryam W. Bridle and Dr. David Wiseman.
Payne was among a group of four Alberta doctors who, in 2021, filed a lawsuit against Alberta Health Services over a mandatory order(opens in a new tab) for physicians to be vaccinated against COVID-19 while Makis actively speaks out against COVID-19 vaccination and was reprimanded in a 2018 tribunal hearing(opens in a new tab) by the College of Physicians and Surgeons of Alberta.
"As a result of the hearing the Tribunal has been, and remains, concerned both for Dr. Makis' fitness to practice, and as a result, for the safety of the public," the hearing said.
Meanwhile, Shoemaker had his licence suspended(opens in a new tab) by the College of Physicians and Surgeons of Ontario (CPSO) in January 2023 over allegations of professional misconduct.
"(Shoemaker) has engaged in an act or omission relevant to the practice of medicine that, having regard to all the circumstances, would reasonably be regarded by members as disgraceful, dishonourable or unprofessional," the CPSO said.
covid-19-vaccine-saskatchewan-1-5878655-1651081173459.jpg
A family arrives for an appointment at a COVID-19 immunization clinic in Regina, Wednesday, Nov. 24, 2021. THE CANADIAN PRESS/Michael Bell
Rose, who the UCP says recently testified before Congress about plasma DNA in COVID-19 injections, withdrew one of her 2021 National Library of Medicine publications(opens in a new tab) about myocarditis adverse events in association with the vaccine and has spoken out against the CDC's vaccine adverse event reporting system(opens in a new tab), calling it "poorly designed and badly implemented."
Bridle, an Ontario veterinarian, sued the University of Guelph, a number of faculty members and other individuals in 2022 for treating him unfairly over his views on the COVID-19 vaccine(opens in a new tab).
The lawsuit sought $3 million in damages including loss of income, equipment and lab materials as well as damage to his career and "mental anguish."

In a separate court case, Bridle was called to provide expert testimony for an Ontario mother battling her husband over whether or not their 11-year-old child would be vaccinated against COVID-19(opens in a new tab).
The father's expert witness was University of Toronto infectious diseases specialist Dr. Abdu Sharkawy.
Justice Sheilagh O'Connell ruled in favour of the father of the child in that case, giving him "sole authority to make decisions about all vaccinations to be administered to the child going forward."
moderna-covid-19-vaccine-1-6065075-1663001521253.jpg
A vial of the Moderna COVID-19 vaccine rests on a table at an inoculation station next to Jackson State University in Jackson, Miss., Tuesday, July 19, 2022. (AP Photo/Rogelio V. Solis, File, File)

'Several successful town halls'​

Bouchard, in a statement to CTV News on Monday, said the meeting is being hosted by his constituency association.
"We have had several successful town halls about issues my constituents care about and they have all been incredibly well attended and well received," he said. "We always welcome diverse viewpoints and open dialogue because it's important for people to listen to different ideas and perspectives, even if they disagree."
He added that he owned a business that was "adversely affected by mandates, lockdowns and restrictions" during the pandemic.
"I believe in advocating for a better approach to dealing with businesses during emergency situations."
He declined further requests from CTV News for an interview.
CTV News reached out to the Alberta government for comment. The following statement from Premier Danielle Smith was provided:
"As Premier, I represent and govern on behalf of all Albertans, and I take my direction from all Albertans. As part of the grassroots party process, our members put forward and vote on policy at our party's AGM," the statement read.
"Minister of Health, Adrianna LaGrange, will continue to work with public health experts to review the international evidence and the safety and efficacy of all vaccines. It is important to note that the COVID-19 vaccine for children is not mandatory, and parents have the choice to decide what’s right for their own family.
"I'm not involved in this event and I do not plan to attend. Any questions about it or the speakers should be directed to the party."
LaGrange, meanwhile, said the following:
"This is being put on by a constituency Association in Calgary. And so, you know, you really need to go and talk to them about who their speakers are and why they're putting this forward," she said.
"We have vaccines COVID vaccines available for children. They've been in existence since 2022 here in the province, and parents do have that option to choose what is best for their family and make those decisions informed by talking to their primary care provider.
"We will always and I will always look at emerging evidence, etc., but these vaccines are available for children and parents do have the right to choose."
(With files from CTV Calgary's Teri Fikowski and CTV Kitchener)
 

KP.2 is now the dominant COVID variant. Experts say US may see a summer increase in cases​

KP.2 currently makes up an estimated 28.2% of cases in the U.S., CDC data shows.
ByMary Kekatos
May 13, 2024, 5:07 PM




Covid-summer-1-gty-jm-240513_1715608398059_hpMain_16x9.jpg


3:11

What we learned about long COVID 4 years later
What we learned about long COVID 4 years later
Millions of Americans are still experiencing long COVID more than four years since the glo...Show More


For the last few months, JN.1 has been the dominant COVID-19 variant in the United States, making up the majority of cases. A new variant, however, has taken over and may lead to an increase in cases this summer.
KP.2, which is an offshoot of the omicron variant, currently accounts for an estimated 28.2% of COVID cases after making up just 1.4% of cases in mid March, according to data from the Centers for Disease and Prevention.
Over the past four years, the U.S. has seen summer waves of COVID and this summer may also bring a rise in cases, but not severe as in past seasons.

MORE: COVID-19 hospitalizations hit record low, the CDC says​




"We've had four consecutive increases of COVID in the summers in the last four years," Dr. Peter Chin-Hong, a professor of medicine and an infectious disease expert at the University of California, San Francisco (UCSF), told ABC News. "We expect an increase this summer too, but it probably won't be large and it probably won't be as profound as wintertime."
Chin-Hong said he would refer to the increase as more of a "swell" rather a "wave" or a "surge."
PHOTO: COVID Variant Estimated Proportions in the United States

COVID Variant Estimated Proportions in the United States
ABC News, CDC
"Like when you're at the beach and you see the swell coming," he explained. "It's not like a tsunami, it's not like a huge wave crashing, it's just kind of like a little swell. But the swell does mean that some people are going to get sick."
Early data indicates KP.2 has more mutations to the spike protein than JN.1, which the virus uses to attach to -- and infect – cells, which could potentially make KP.2 more infectious.
"The virus' capacity to evolve is anticipated, and it's something we've prepared for in our ongoing public health response," said Dr. John Brownstein, an epidemiologist and chief innovation officer at Boston Children's Hospital and an ABC News contributor. "Given the seasonal patterns observed with COVID-19, a slight uptick in cases could be anticipated this summer, making ongoing surveillance and vaccination efforts all the more essential."
Experts say there is no clear evidence that KP.2 -- which some scientists have nicknamed "FLiRT" on social media but is not an official name used by the CDC or the World Health Organization -- causes more severe illness or is more deadly than previous variants.
While more studies are needed to see if KP.2 is better at evading current vaccines than other variants, Chin-Hong said his experience at UCSF's hospital over the past few weeks seems to indicate that vaccines are continuing to provide good protection.

He said the one common factor among all the patients hospitalized at UCSF with severe COVID is that none of them received the updated COVID vaccine that rolled out in fall 2023.

"If you haven't done, go ahead and get it," Chin-Hong said.

MORE: Nursing homes wield pandemic immunity laws to duck wrongful death suits​




He added that it's especially important for those who are immunocompromised or more susceptible to severe disease, such as being aged 65 and over, to get vaccinated.
COVID hospitalizations have not been increasing in the U.S., a milestone for the nation.
In late April, the latest week for which data is available, the U.S. hit 5,615 COVID weekly hospitalizations. By comparison, there were more than 150,000 weekly admissions at the peak of the omicron variant circulating in early 2022.
PHOTO: A masked family walks through Universal CityWalk in Orlando, FL, June 14, 2022.

A masked family walks through Universal CityWalk in Orlando, FL, June 14, 2022.
Stephen M. Dowell/Orlando Sentinel/TNS via Getty Images
Experts say the U.S. is in a much better place to fight COVID than at the start of the pandemic and new variants are a reminder to remain vigilant, but not to panic.
"We have to remember this virus is now part of the respiratory mix we handle yearly just like influenza and, just like influenza, we try to stay ahead of the game to prepare for any possible surge or to understand how well the vaccines are matched," Brownstein said. "This is all bread-and-butter public health surveillance. It's important to stay up-to-date with vaccines and remain vigilant and stay home when sick."
 

CDC sounds the alarm on new COVID variant​


 

UCSF infectious disease specialist explains new COVID variants​


 

SHOCKING: Covid Vaccine Injury Claims IGNORED By Government, Big Pharma SHIELDED​


 

Novavax stock doubles after Sanofi deal marks 'new chapter' for company​


Anjalee Khemlani
Anjalee Khemlani
·Senior Reporter
Fri, May 10, 2024, 4:08 PM GMT-44 min read

11
In This Article:
Novavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi (SNY) would invest $1.2 billion in a deal for Novavax's COVID-19 vaccine and take a minority stake in the struggling biotech company.
The deal gave Novavax a much-needed cash boost as the company had flagged after a pandemic-era surge.

"This is a new chapter in the history of our company," Novavax CEO John Jacobs told Yahoo Finance in an interview Friday.
Novavax, Inc. (NVAX)
View quote details
NasdaqGS - Nasdaq Real Time Price (USD)
13.48
+0.37(2.82%)
At close:4:00PM EDT
13.01-0.47 (-3.49%)
Pre-market: 7:13AM EDT
Add to watchlist
  • 1D
  • 5D
  • 1M
  • 6M
  • YTD
  • 1Y
  • 5Y
  • Max
Full screen
NVAXSNY
Novavax struggled after its COVID-19 vaccine was delayed by manufacturing issues early in development, which resulted in the company missing out on the multibillion-dollar pandemic boom that Pfizer/BioNTech (PFE/BNTX) and Moderna (MRNA) enjoyed.
While Novavax's vaccine did finally reach the market in mid-2022 targeting the booster market, it continued to struggle with $1.7 billion in liabilities of promised COVID doses globally weighing on its books.
The news, which overshadowed Novavax's first quarter earnings release on Friday, has turned the company around from near failure.
"This company was likely headed for real trouble, and we put a going concern on the company my second month on the job," Jacobs said.
Jacobs took the helm from longtime CEO Stanley Erck in January 2023. In the 15 months since, he has decreased the company's liabilities to $1.7 billion, compared to a previous $2.5 billion, and reduced expenses from manufacturing and R&D.
"[This] in and of itself doesn't save Novavax, but what it does ... is now put us toward a future of growth back on our biotech strength, back on a platform-based growth strategy that allows us to drive growth," Jacobs said.
The deal with Sanofi includes a $500 million up-front payment to Novavax and up to $700 million as certain milestones are met for COVID-19 vaccine co-commercialization, the development of a combination COVID-flu vaccine, and royalties. Sanofi is licensing the technology for the combination COVID-flu vaccine, which is separate from the one currently in Novavax's pipeline.
In addition to that $1.2 billion, Sanofi is committing up to $200 million for each new vaccine it develops using Novavax's technology. That represents a multibillion-dollar future for the company, Novavax CFO Jim Kelly said on the company's earnings call Friday.
On top of all that, Sanofi is acquiring a minority stake through a $70 million equity investment.
Photo by: STRF/STAR MAX/IPx 2021 1/29/21 Novavax says their two-shot vaccine for COVID-19 shows an efficacy rate of 89.3% in a major Phase 3 clinical trial and was highly effective against a variant first identified in the U.K.. STAR MAX Photo: Novavax logo and COVID-19 virus images photographed off Apple devices.

Novavax logo and COVID-19 virus images photographed off Apple devices. (STRF/STAR MAX/IPx) (STRF/STAR MAX/IPx)

A platform match​

The investment from Sanofi, a small fraction of the company's $46.2 billion annual revenue in 2023, is not so significant.
But Sanofi is one of the world's largest vaccine makers and has a robust flu portfolio that accounted for $2.8 billion of its total $8 billion in vaccine revenues last year.
Novavax and Sanofi have similar platforms for their vaccines using recombinant protein, a well-known formula that provides long-term protection. The platform is used in Sanofi's flu vaccine, Flublok, which along with its Fluzone for older adults, accounts for $2.8 billion of Sanofi's annual $8 billion vaccine portfolio.
Amid the vaccine race early in the pandemic, the scientific community was eager to see these types of vaccines reach the finish line.
"As we headed into December 2020, it was obvious that the first two vaccines we were to consider were mRNA vaccines, where we had no experience with that technology," said Dr. Paul Offit, director of the vaccine education center and a pediatrician at the Children's Hospital of Philadelphia.
"Novavax, on the other hand, was a tried-and-true technology," Offit, who also served as a member on the advisory committee for the Centers for Disease Control and Prevention (CDC), told Yahoo Finance.
Like Novavax, Sanofi similarly missed the pandemic market after its vaccine candidate, in partnership with GSK (GSK), was delayed during clinical trials. The duo was also late to the market with the vaccine in 2022 in Europe and targeted the booster market.
When asked if Sanofi had previously approached Novavax for partnership, CEO Jacobs said he couldn't comment.
"I'm actually not sure if that ever occurred before my time," Jacobs said. "I have to believe that over time Novavax might have had conversations with other companies, but until these barriers [liabilities] were removed ... I don't think we were a very attractive target for significant business development because there was so much uncertainty."
He added that if there were ever a discussion in the future of a sale or acquisition, the board "would always consider appropriately for our shareholders the right path to value."
Novavax beat on earnings per share, at $1.08 versus consensus estimates of $1.05, but it missed on revenues, reporting $98.3 million compared to Wall Street expectations of more than $101 million.
 

Users who are viewing this thread

Country Watch Latest

Back
Top